一例晚期胃印戒细胞癌经信迪利单抗联合化疗后出现弥漫性血管内凝血
A Case of Advanced Gastric Signet Ring Cell Carcinoma Exhibited Diffuse Intravascular Coagulation Following the Administration of Sintilimab in Combination with Chemotherapy
DOI: 10.12677/acm.2024.1461743, PDF,   
作者: 谭 政, 宫苏敏：莱阳市中医医院药剂科，山东 烟台；王 振：南京医科大学临床医学院，江苏 南京；黄 璐：萍矿总医院肿瘤科，江西 萍乡；郎连群*：青岛市市立医院肿瘤科，山东 青岛；陈 琦*：菏泽市定陶区人民医院药剂科，山东 菏泽
关键词: 晚期胃印戒细胞癌；信迪利单抗；弥漫性血管内凝血；免疫相关不良事件；病例分析；Advanced Gastric Signet Ring Cell Carcinoma； Sintilimab； Diffuse Intravascular Coagulation； Immune-Related Adverse Events； Case Analysis
摘要: 本文报道了信迪利单抗联合化疗致弥漫性血管内出血，经治疗后好转的病例。通过回顾信迪利单抗相关不良反应的文献资料，进一步分析信迪利单抗联合化疗所致弥漫性血管内凝血的临床特点、发病机制。在此过程中临床药师积极参与，协助临床优化治疗方案，提高信迪利单抗临床应用的安全性。
Abstract: This article reports a case of diffuse intravascular hemorrhage caused by the administration of sintilimab in combination with chemotherapy, which improved following treatment. Through a review of the literature on adverse reactions associated with sintilimab, a further analysis is conducted on the clinical characteristics and pathogenesis of diffuse intravascular coagulation resulting from its combined use with chemotherapy. Clinical pharmacists actively participated in this process, assisting in optimizing treatment regimens and enhancing the safety of sintilimab in clinical applications.
文章引用：谭政, 王振, 宫苏敏, 黄璐, 郎连群, 陈琦. 一例晚期胃印戒细胞癌经信迪利单抗联合化疗后出现弥漫性血管内凝血[J]. 临床医学进展, 2024, 14(6): 45-51. https://doi.org/10.12677/acm.2024.1461743

参考文献

[1] Wang, J., Fei, K., Jing, H., et al. (2019) Durable Blockade of PD-1 Signaling Links Preclinical Efficacy of Sintilimab to Its Clinical Benefit. MAbs, 11, 1443-1451. [Google Scholar] [CrossRef] [PubMed]
[2] Shi, Y., Su, H., Song, Y., et al. (2019) Safety and Activity of Sintilimab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial. The Lancet Haematology, 6, E12-E19. [Google Scholar] [CrossRef] 
[3] Zhang, L., Wang, Z., Fang, J., et al. (2022) Final Overall Survival Data of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. Lung Cancer, 171, 56-60. [Google Scholar] [CrossRef] [PubMed]
[4] Zhang, Z., Ye, J., Li, H., et al. (2022) Neoadjuvant Sintilimab and Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Single-Arm, Phase 2 Trial. Frontiers in Immunology, 13, Article ID: 1031171. [Google Scholar] [CrossRef] [PubMed]
[5] Guo, C., Zhang, J., Huang, X., et al. (2023) Preoperative Sintilimab plus Transarterial Chemoembolization for Hepatocellular Carcinoma Exceeding the Milan Criteria: A Phase II Trial. Hepatology Communications, 7, E0054. [Google Scholar] [CrossRef] 
[6] Guo, X., Yang, B., He, L., et al. (2022) PD-1 Inhibitors plus Oxaliplatin or Cisplatin-Based Chemotherapy in First-Line Treatments for Advanced Gastric Cancer: A Network Meta-Analysis. Frontiers in Immunology, 13, Article ID: 905651. [Google Scholar] [CrossRef] [PubMed]
[7] 徐鲁杰, 刘畅, 闫美兴, 等. 信迪利单抗致免疫相关性不良反应的两例报道并文献复习[J]. 临床药物治疗杂志, 2022, 20(1): 82-85.
[8] 庄大洁, 吴立平. 信迪利单抗药物不良反应及文献分析[J]. 中国药事, 2023, 37(1): 102-108.
[9] 吕亚青, 李崇鑫, 吕增波, 等. 信迪利单抗致自身免疫性溶血性贫血1例[J]. 医药导报, 2023, 42(10): 1580-1582.
[10] 姚欣凯, 穆新林, 张海英. 4种准入中国医保的PD-1抑制剂药学特性及临床应用评价[J]. 中国现代应用药学, 2022, 39(7): 952-959.
[11] Sibaud, V. (2018) Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. American Journal of Clinical Dermatology, 19, 345-361. [Google Scholar] [CrossRef] [PubMed]
[12] 濮晓燕, 潘晓东, 戴安印, 郭胜才. 信迪利单抗致免疫相关性不良反应文献分析[J]. 中国药物应用与监测, 2023, 20(1): 36-39 44.
[13] Smeekens, M., Wouters, M., de Jong, P., et al. (2018) Disseminated Intravascular Coagulation in a Patient with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 13, e224-e225. [Google Scholar] [CrossRef] [PubMed]
[14] Gupta, A., Madhavan, M.V., et al. (2020) Extrapulmonary Manifestations of COVID-19. Nature Medicine, 26, 1017-1032. [Google Scholar] [CrossRef] [PubMed]
[15] 吴娇, 王沛纯, 刘璇. 新型冠状病毒肺炎患者中的凝血功能异常及其可能机制和治疗策略[J]. 上海中医药大学学报, 2022, 36(6): 90-100.
[16] Levi, M. and Sivapalaratnam, S. (2018) Disseminated Intravascular Coagulation: An Update on Pathogenesis and Diagnosis. Expert Review of Hematology, 11, 663-672. [Google Scholar] [CrossRef] [PubMed]
[17] Alberti, A., Mancin, M., Cortinovis, D., et al. (2020) Disseminated Intravascular Coagulation in Advanced Lung Adenocarcinoma during First-Line Pembrolizumab. Immunotherapy, 12, 629-633. [Google Scholar] [CrossRef] [PubMed]
[18] Sato, R., Imamura, K., Sakata, S., et al. (2019) Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. Clinical Medicine, 8, Article No. 762. [Google Scholar] [CrossRef] [PubMed]
[19] 国家药品不良反应监测中心. 药品不良反应术语使用指南[S]. 北京: 国家药品不良反应监测中心, 2016.
[20] Huang, A.C., Postow, M.A., Orlowski, R.J., et al. (2017) T-Cell Invigoration to Tumour Burden Ratio Associated with Anti-PD-1 Response. Nature, 545, 60-65. [Google Scholar] [CrossRef] [PubMed]
[21] Boussiotis, V.A. (2016) Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. The New England Journal of Medicine, 375, 1767-1778. [Google Scholar] [CrossRef] 
[22] Delanoy, N., Michot, J.-M., Comont, T., et al. (2019) Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: A Descriptive Observational Study. The Lancet Haematology, 6, E48-E57. [Google Scholar] [CrossRef] 
[23] Kramer, R., Zaremba, A., Moreira, A., et al. (2021) Hematological Immune Related Adverse Events after Treatment with Immune Checkpoint Inhibitors. European Journal of Cancer, 147, 170-181.

为你推荐